Kamada (KMDA) stock: key figures, P/E, revenue and dividend
Health Care · Biotechnology · United States · ISIN IL0010941198
Kamada financials
| Fiscal year | 2024 | 2025 |
|---|---|---|
| Revenue | 160.95 m USD | 180.46 m USD |
| Gross profit | 69.97 m USD | 76.41 m USD |
| Operating income | 20.05 m USD | 26.23 m USD |
| EBIT | 13.99 m USD | 24.33 m USD |
| Net income | 14.46 m USD | 20.20 m USD |
| Diluted EPS – continuing operations | 0.25 USD | 0.35 USD |
Full history since 2007, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About Kamada
Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its products include KAMRAB/KEDRAB indicated as prophylaxis of rabies; CYTOGAM for prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM for prophylaxis of hemolytic disease of newborns; and Echis coloratus and Vipera palaestinae Antiserum to treat snake bite. The company also distributes biopharmaceutical products in Israel, including BRAMITOB to manage chronic pulmonary infection; FOSTER to treat asthma; TRIMBOW for chronic obstructive pulmonary disease; PROVOCHOLINE for the diagnosis of bronchial airway hyperactivity; AEROBIKA, an OPEP device; RUPAFIN and RUPAFIN ORAL SOLUTION for allergic rhinitis and Urticaria; SINTREDIUS for rheumatoid arthritis, systemic lupus erythematosus, and mild-moderate juvenile dermatomyositis; IVIG for various immunodeficiency-related conditions; VARITECT for chicken pox and zoster herpes; ZUTECTRA and HEPATECT CP for prevention of hepatitis B; MEGALOTECT CP for CMV virus; RUCONEST for angioedema attack; HEPARIN SODIUM INJECTION for thrombo-embolic disorders and prophylaxis of deep vein thrombosis and thromboembolic events; ALBUMIN and ALBUMIN for blood plasma; Factor VIII for hemophilia type A; and Factor IX for hemophilia type B. In addition, it distributes COAGADEX to treat hereditary factor X deficiency; IXIARO for Japanese encephalitis; VIVOTIF for salmonella typhi; PROCYSBI for nephropathic cystinosis; LAMZEDE for alpha-mannosidosis; RYPLAZIM for hypoplasminogenemia; ELIGARD for prostate cancer; and BEVACIZUMAB KAMADA for various cancers. The company was incorporated in 1990 and is headquartered in Rehovot, Israel.
More stocks
- Guangdong Sanhe Pile Co Ltd (003037.SZ)
- Shenzhen King Brother Electronics Technology Co.Ltd. (301041.SZ)
- Gongwin Biopharm Holdings Co. Ltd. (6617.TWO)
- Elridge Energy Holdings Berhad (0318.KL)
- Hanssem (009240.KS)
- TEJON RANCH CO (TRC)
- Note AB (publ) (NOTE.ST)
- POET Technologies Inc (POET)
- LUXFER HOLDINGS PLC (LXFR)
- Ningbo Jianan Electronics Co Ltd (300880.SZ)
- ChinaEtek Service & Technology Co. Ltd. (301208.SZ)
- WABASH NATIONAL Corp (WNC)
Not investment advice. All data without warranty, price as of 10.11.2026. Details in the risk notice.